137 related articles for article (PubMed ID: 31542640)
1. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials.
Davidson M; Wagner AD; Kouvelakis K; Nanji H; Starling N; Chau I; Watkins D; Rao S; Peckitt C; Cunningham D
Eur J Cancer; 2019 Nov; 121():40-47. PubMed ID: 31542640
[TBL] [Abstract][Full Text] [Related]
2. Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).
Athauda A; Nankivell M; Langley RE; Alderson D; Allum W; Grabsch HI; Starling N; Chau I; Cunningham D
Eur J Cancer; 2020 Sep; 137():45-56. PubMed ID: 32745964
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
Bamias A; Cunningham D; Nicolson V; Norman A; Hill M; Nicolson M; O'Brien M; Webb A; Hill A
Br J Cancer; 1995 Mar; 71(3):583-6. PubMed ID: 7880742
[TBL] [Abstract][Full Text] [Related]
4. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Chau I; Norman AR; Cunningham D; Oates J; Hawkins R; Iveson T; Nicolson M; Harper P; Seymour M; Hickish T
Ann Oncol; 2009 May; 20(5):885-91. PubMed ID: 19164454
[TBL] [Abstract][Full Text] [Related]
5. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
Al-Batran SE; Pauligk C; Homann N; Hartmann JT; Moehler M; Probst S; Rethwisch V; Stoehlmacher-Williams J; Prasnikar N; Hollerbach S; Bokemeyer C; Mahlberg R; Hofheinz RD; Luley K; Kullmann F; Jäger E
Eur J Cancer; 2013 Mar; 49(4):835-42. PubMed ID: 23063354
[TBL] [Abstract][Full Text] [Related]
6. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Tebbutt NC; Price TJ; Ferraro DA; Wong N; Veillard AS; Hall M; Sjoquist KM; Pavlakis N; Strickland A; Varma SC; Cooray P; Young R; Underhill C; Shannon JA; Ganju V; Gebski V
Br J Cancer; 2016 Mar; 114(5):505-9. PubMed ID: 26867157
[TBL] [Abstract][Full Text] [Related]
7. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
8. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
Wheatley-Price P; Le Maître A; Ding K; Leighl N; Hirsh V; Seymour L; Bezjak A; Shepherd FA;
J Thorac Oncol; 2010 May; 5(5):640-8. PubMed ID: 20354457
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
Mackay HJ; McInnes A; Paul J; Raby N; Lofts FJ; McDonald AC; Soukop M; Fullarton GM; Harris AL; Garcia-Vargas J; Evans TR
Ann Oncol; 2001 Oct; 12(10):1407-10. PubMed ID: 11762812
[TBL] [Abstract][Full Text] [Related]
10. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.
Sylvie L; Silvia S; Salah-Eddin AB; Markus F; Florian L; Peter TP; Bernhard H; Martin A; Alexander N
Eur J Cancer; 2015 Sep; 51(14):1918-26. PubMed ID: 26216588
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.
Hawkes E; Okines AF; Papamichael D; Rao S; Ashley S; Charalambous H; Koukouma A; Chau I; Cunningham D
Eur J Cancer; 2011 May; 47(8):1146-51. PubMed ID: 21269822
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index.
Gresham G; Diniz MA; Razaee ZS; Luu M; Kim S; Hays RD; Piantadosi S; Tighiouart M; Yothers G; Ganz PA; Rogatko A
J Natl Cancer Inst; 2020 Dec; 112(12):1266-1274. PubMed ID: 32091598
[TBL] [Abstract][Full Text] [Related]
14. Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Jun; 18(2):110-115.e2. PubMed ID: 30679026
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Assersohn L; Brown G; Cunningham D; Ward C; Oates J; Waters JS; Hill ME; Norman AR
Ann Oncol; 2004 Jan; 15(1):64-9. PubMed ID: 14679122
[TBL] [Abstract][Full Text] [Related]
16. TOXview: a novel graphical presentation of cancer treatment toxicity profiles.
Ngai LL; Ter Veer E; van den Boorn HG; van Herk EH; van Kleef JJ; van Oijen MGH; van Laarhoven HWM
Acta Oncol; 2019 Aug; 58(8):1138-1148. PubMed ID: 31017020
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction.
Samel S; Hofheinz R; Hundt A; Sturm J; Knoll MR; Wenz F; Queisser W; Post S
Onkologie; 2001 Jun; 24(3):278-82. PubMed ID: 11455222
[TBL] [Abstract][Full Text] [Related]
19. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
20. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
Eatock MM; Anthony DA; El-Abassi M; Wilson P; Paul J; Smith M; Soukop M; Evans TR
Br J Cancer; 2000 Jun; 82(12):1925-31. PubMed ID: 10864199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
